資源描述：
《吡喃阿霉素與奧沙利鉑治療原發(fā)性肝癌的比較分析.doc》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫(kù)。
1、毗喃阿霉素與奧沙利鉗治療原發(fā)性肝癌的比較分析［摘要］目的比較奧沙利伯和叱喃阿霉素對(duì)原發(fā)性肝癌的臨床治療效果，為原發(fā)性肝癌選擇臨床化療方案提供依據(jù),以達(dá)到治療方案合理、有效、安全、經(jīng)濟(jì)的目的。方法整群選取2013年9月一2015年3月到該院住院治療的原發(fā)性肝癌患者158例，將患者隨機(jī)分為兩組，每組79例；治療時(shí)，觀察組患者給予奧沙利伯，對(duì)照組給予毗喃阿霉素，比較兩組患者治療有效率、不良反應(yīng)發(fā)生率、病程進(jìn)展時(shí)間、臨床癥狀改善率等。結(jié)果觀察組的患者治療有效率為79.75%,對(duì)照組為60.76%,結(jié)果表明觀察組的治療效果明顯高于對(duì)照組，對(duì)照組病情無(wú)進(jìn)展時(shí)間為(6±2
2、.4)個(gè)月，觀察組病情無(wú)進(jìn)展時(shí)間為(9±3.1)個(gè)月，觀察組疾病無(wú)進(jìn)展時(shí)間比對(duì)照組長(zhǎng)；另外，觀察組患者不良反應(yīng)發(fā)生率和臨床癥狀改善率與對(duì)照組相比無(wú)明顯優(yōu)勢(shì)。結(jié)論從不良反應(yīng)發(fā)生率和臨床癥狀改善率來(lái)看，毗喃阿霉素和奧沙利伯治療原發(fā)性肝癌無(wú)差異，但奧沙利伯對(duì)原發(fā)性肝癌的治療效果和病情控制效果比毗喃阿霉素好，值得臨床推廣。［關(guān)鍵詞］毗喃阿霉素；奧沙利伯；原發(fā)性肝癌［中圖分類號(hào)］R735［文獻(xiàn)標(biāo)識(shí)碼］A［文章編號(hào)］1674-0742(2015)11(b)-00119-02［Abstract］ObjectiveTocomparetheclinicaleffect,ofp
3、irarubicinandoxaliplatinintreatmentofpatientswithprimarylivercancersoastoprovidebasisforselectingclinicalchemotherapyregimenstomakethetreatmentmorerational，effective,safeandeconomicaLMethods158patientswithprimarylivercanceradmittedtoourhospitalfromSeptember2013toMarch2015wereselect
4、edandrandomlydividedintothestudygroupandthecontrolgroup,with79casesineachgroup.Thestudygroupwastreatedwithoxaliplatin,whilethecontrolgroupwastreatedwithpirarubicin.Theresponserate,incidenceofadversereaction,disease-progression-freeduration,improvementrateofclinicalsymptomswasobserv
5、edandcomparedbetweentwogroups.ResultsTheresponseratewas79.75%inthestudygroupand60.76%inthecontrolgroup,andtheresultsshowedthattheresponserateofstudygroupwassignificantlyhigherthanthatofthecontrolgroup.Thedisease-progression-freeduration[(6+2.4)mvs(9+3.1)m]wasshorterinthecontrolgrou
6、pthanintheobservationgroup.Nostatisticallysignificantdifferencecanbefoundintheimprovementrateofclinicalsjnnptomsandincidenceofadversereactionbetweenthestudygroupandthecontrolgroup.ConclusionIntermsofincidenceofadversereactionandimprovementrateofclinicalsymptoms,therewasnostatistica
7、llysignificantdifferencebetweenpirarubicinandoxaliplatinintreatmentofpatientswithprimarylivercancer.Butoxaliplatinhasbettereffectandcanbettercontrolthedisease,thereforeitisworthyofpromotion.[Keywords]Pirarubicin；Oxaliplatin；Primarylivercancer原發(fā)性肝癌（IICC,以下簡(jiǎn)稱肝癌）是起源于肝臟的間葉組織或上皮的惡性腫瘤，是一
8、種多基因突變引起的緩慢病變過(guò)程，但發(fā)病機(jī)制和病因尚未
